Patients with LGMD2C-F, in particular with β-sarcoglycan deficient (LGMD2E) and δ-sarcoglycan-deficient (LGMD2F), often develop a progressive and potentially fatal DCM in association with muscular dystrophy (Politano et al., 2001). Here, SGCG is linked to hyperinsulinemic hypoglycemia, familial, 4.